Interview: Judith Greciet – CEO, Onxeo, France
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Mayoly Spindler is an independent French family-run pharmaceutical company which has been able to grow for several decades through effective and recognized pharmaceutical products. Its know-how mainly covers gastroenterology, rheumatology, ENT, and dermocosmetics in order to diversify its activities. Mayoly Spindler has more than 700 employees. Their vision is to become a reference company internationally in the field of gastroenterology and dermocosmetics. Forty-five percent of their business is done overseas; and on current projections, excluding external growth, this is expected to grow by 60 percent by 2020. The international sphere is a springboard for growth, focusing on developing sales in key zones; including markets such as China.
Contact
Address: 6 Avenue de l’Europe, 78401 Chatou Cedex, France
Phone:+33 1 34 80 55 55
Web: mayoly-spindler.fr
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Patrick Choay discusses his first foray into the pharmaceutical business world, talks about the highlights of his long and interesting career, his balanced partnership strategy for the Choay Group and…
Marc-Antoine Lucchini, the president-general manager of Sanofi France, talks about their unprecedented number of new molecules and innovations soon to be launched. He also explains the need to focus on the…
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
The CEO of Medicen Paris Region, the biopharma cluster for the Paris region, discusses her vision to develop a world-class cluster and act as a catalyst for innovation; her international…
Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third…
Mr Truelle, the CEO of CDM Lavoisier, a company specialized in the pharmaceutical manufacturing of injectable solutions, reveals that one third of the French population could receive one of the…
Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape…
Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented…
The President of Pfizer France reveals how the biggest challenge the French pharma industry faces is to gain credit for its contribution to improve people´s quality of life; why France…
The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with…
Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic…
See our Cookie Privacy Policy Here
